Cero Therapeutics Faces Delisting Concerns
Ticker: CEROW · Form: 8-K · Filed: Sep 4, 2025 · CIK: 1870404
Sentiment: bearish
Topics: delisting, listing-rule, biotech
Related Tickers: CERO
TL;DR
CERO might get delisted, stock could tank.
AI Summary
Cero Therapeutics Holdings, Inc. filed an 8-K on August 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Phoenix Biotech Acquisition Corp., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing indicates potential issues with Cero Therapeutics' continued listing on an exchange, which could impact its stock value and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Players & Entities
- CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
- August 28, 2025 (date) — Date of earliest event reported
- Phoenix Biotech Acquisition Corp. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific listing rule or standard has Cero Therapeutics Holdings, Inc. failed to satisfy?
The filing states it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify which rule was violated in the provided text.
What is the effective date of the delisting notice?
The filing was made as of September 4, 2025, with the date of the earliest event reported being August 28, 2025.
What was Cero Therapeutics Holdings, Inc. previously named?
The company was formerly named Phoenix Biotech Acquisition Corp.
In which state is Cero Therapeutics Holdings, Inc. incorporated?
Cero Therapeutics Holdings, Inc. is incorporated in Delaware.
What is the SIC code for Cero Therapeutics Holdings, Inc.?
The Standard Industrial Classification (SIC) code for Cero Therapeutics Holdings, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 706 words · 3 min read · ~2 pages · Grade level 14.3 · Accepted 2025-09-04 16:05:29
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share CERO NASDAQ Capital Marke
- $2,500,000 — mum stockholders' equity requirement of $2,500,000 (the " Stockholders' Equity Requirement
Filing Documents
- ea0255967-8k_cero.htm (8-K) — 28KB
- 0001213900-25-084498.txt ( ) — 235KB
- cero-20250828.xsd (EX-101.SCH) — 4KB
- cero-20250828_def.xml (EX-101.DEF) — 26KB
- cero-20250828_lab.xml (EX-101.LAB) — 36KB
- cero-20250828_pre.xml (EX-101.PRE) — 25KB
- ea0255967-8k_cero_htm.xml (XML) — 6KB
01. Notice of Delisting or Failure to Satisfy a Continued
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 28, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the " Company "), received a letter from the staff at the Nasdaq Listing Qualifications department notifying the Company that such staff had determined that the Company does not comply with the minimum stockholders' equity requirement of $2,500,000 (the " Stockholders' Equity Requirement ") for continued listing on the Nasdaq Capital Market (" Nasdaq ") set forth in Nasdaq Rule 5550(b). As previously disclosed, the Company previously had been out of compliance with Nasdaq continued listing requirements until, on May 7, 2025, the Company received a determination of a Nasdaq hearings panel (a " Hearings Panel ") that it had regained compliance with such requirements. Pursuant to Nasdaq Rule 5815(d)(4)(B), the Company is subject to a mandatory hearings panel monitor until one year after regaining compliance with such requirements. As a result, Nasdaq staff lack the discretion to grant the Company a cure period for demonstrating regaining compliance with the Stockholders' Equity Requirement. The Nasdaq staff indicated that the Company's securities would be suspended from trading on Nasdaq and delisted on September 8, 2025, subject to the Company's right to appeal described below. On September 3, 2025, the Company requested a hearing to appeal such determination before a panel (the " Hearings Panel "). The hearing request will stay the suspension of the trading of the Company's common stock and delisting thereof pending such hearing or any extension provided by the Hearings Panel. At such hearing, the Company intends to submit a plan to regain compliance with the Stockholders' Equity Requirement. Such plan of compliance may include the increase in stockholders' equity through the consummation of public or private financing transactions. No assurances can be provided that the Com